Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel F Petricoin

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Chemistry|July 9, 2008
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirementsCatharine M Sturgeon, Barry R Hoffman, Daniel W Chan, et al.
Cancer Research|September 23, 2003
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profilingSatoshi Nishizuka, Sing-Tsung Chen, Fuad G Gwadry, et al.
The American Journal of Pathology|February 13, 2002
Evaluation of non-formalin tissue fixation for molecular profiling studiesJohn W Gillespie, Carolyn J M Best, Verena E Bichsel, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Chemistry|July 9, 2008
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirementsCatharine M Sturgeon, Barry R Hoffman, Daniel W Chan, et al.
Cancer Research|September 23, 2003
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profilingSatoshi Nishizuka, Sing-Tsung Chen, Fuad G Gwadry, et al.
The American Journal of Pathology|February 13, 2002
Evaluation of non-formalin tissue fixation for molecular profiling studiesJohn W Gillespie, Carolyn J M Best, Verena E Bichsel, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.
Pageof 2